



FILE NO. 31064 070165.0447

*K. T. 10/98*  
*#5*  
*8/7/98*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Podos et al.  
Serial No. : 08/853,803 Examiner: Z. Fay  
Filed : May 9, 1997 Group Art Unit: 1614  
For : NOVEL PROSTAGLANDINS FOR GLAUCOMA THERAPY

AMENDMENT

I hereby certify that this paper is being deposited with the United States  
Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231

July 29, 1998  
Date of Deposit

Lisa B. Kole  
Attorney Name  
*Lisa B. Kole*  
Signature

35,225  
PTO Registration No.  
July 29, 1998  
Date of Signature

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Official Action dated April 29, 1998, please consider the  
following remarks.


The Examiner has rejected the claims over DeSantis et al., United States  
Patent No. 5,565,492. According to the Examiner, DeSantis teaches the use of  
prostaglandin E, its derivatives and analogues for the treatment of glaucoma. The  
Examiner contends that the claims are obvious under 35 U.S.C. §103 because the  
compounds of the claims have been used in the treatment of glaucoma and Applicants  
have shown no evidence of the unexpected and unobvious nature of the claimed subject

matter.

Applicants assert that DeSantis does not render the instant claims obvious because the claimed compounds are structurally different from the compounds taught in DeSantis. Virtually all of the prostaglandins disclosed in DeSantis have an opposite geometrical arrangement of side chains relative to the presently claimed compounds. In particular, with respect to the prostaglandin five-membered ring, the attached side chains are *trans* in all of the compounds disclosed in DeSantis, but *cis* in the instantly claimed compounds (hence the "iso" prefix). In view of this structural difference (which is remarked upon in the instant specification at page 6 lines 7-9 of the specification), the skilled artisan would not have reasonably expected the 8-iso-prostaglandins of the invention to be effective in decreasing intraocular pressure.

Accordingly, Applicants request that the rejection be withdrawn and that the claims be allowed to issue.

Respectfully submitted,



---

Richard S. Clark  
Patent Office Reg. No. 26,154

Lisa B. Kole  
Patent Office Reg. No. 35,225  
Attorneys for Applicants